FDA Approves Adrabetadex for Infantile Onset NPC

Company Beren Therapeutics (Mandos subsidiary) Event Type FDA approval Modality Intrathecal cyclodextrin Asset Adrabetadex (Lembaz) Target Lysosomal cholesterol mobilization Disease Area Niemann-Pick disease type C Summary FDA approved intrathecal adrabetadex (Lembaz) for patients with Niemann–Pick disease type C whose neurological symptoms began before age six…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *